Zacks Investment Research downgraded shares of DBV Technologies S.A. (NASDAQ:DBVT) from a buy rating to a hold rating in a research note issued to investors on Thursday.

According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “

DBVT has been the subject of several other research reports. HC Wainwright reaffirmed a buy rating and set a $50.00 price target on shares of DBV Technologies in a report on Thursday, July 6th. BidaskClub raised DBV Technologies from a strong sell rating to a sell rating in a report on Wednesday, June 21st. Deutsche Bank AG assumed coverage on DBV Technologies in a report on Friday, June 23rd. They set a buy rating and a $46.00 price target for the company. ValuEngine raised DBV Technologies from a sell rating to a hold rating in a report on Saturday, June 24th. Finally, Jefferies Group LLC reaffirmed a buy rating on shares of DBV Technologies in a report on Thursday, August 31st. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $50.50.

DBV Technologies (NASDAQ DBVT) opened at 43.26 on Thursday. DBV Technologies has a 12 month low of $31.87 and a 12 month high of $46.33. The company’s market cap is $1.99 billion. The company’s 50-day moving average is $44.12 and its 200-day moving average is $37.74.

COPYRIGHT VIOLATION NOTICE: This story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/09/18/dbv-technologies-s-a-dbvt-rating-lowered-to-hold-at-zacks-investment-research.html.

Hedge funds have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd bought a new position in DBV Technologies during the 2nd quarter worth $222,000. Victory Capital Management Inc. bought a new position in DBV Technologies during the 1st quarter worth $303,000. Airain ltd bought a new position in DBV Technologies during the 2nd quarter worth $333,000. DekaBank Deutsche Girozentrale bought a new position in DBV Technologies during the 1st quarter worth $471,000. Finally, Sit Investment Associates Inc. bought a new position in DBV Technologies during the 2nd quarter worth $698,000. Hedge funds and other institutional investors own 45.52% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Get a free copy of the Zacks research report on DBV Technologies (DBVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Stock Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related stocks with our FREE daily email newsletter.